№ lp_2_1_11248
File format: docx
Character count: 10341
File size: 6403 KB
Guidelines for completing the capsule proposal for Balik-PhD applications. This document outlines the required sections for the proposal, including research title, general and specific aims, research strategy, methodologies, yearly expected results, and proponent profiles.
Note:
Year
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
Australia
Theme:
Medicine, Oncology
Document Type:
Submission Report
Organization / Institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
JANSSEN-CILAG PTY LTD
Target Audience:
Healthcare professionals, regulators
Period of Validity:
Ongoing
Approval Date:
28 March 2023
Modification Date:
December 2022
Year:
2018
Region / City:
Australia
Theme:
Pharmaceutical application
Document Type:
Authority Required listing submission
Agency / Organization:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Orphan Australia Pty Ltd
Target Audience:
Healthcare professionals, regulatory authorities
Effective Period:
Not specified
Approval Date:
12 June 2012
Amendment Date:
Not specified
Year:
2026-2027
Institution:
University of Santo Tomas
Department:
Research Center for Social Sciences and Education (RCSSED)
Document Type:
Research Proposal Form / Project Application
Academic Term:
First Term
Project Duration:
One Academic Year (August 2026 – May 2027)
Funding Source:
UST RCSSED and/or external sources
Proponent Information:
Name, Degree, Affiliation, Academic Rank, Research Interest Group (as applicable)
Collaborators:
Names and Affiliations (if any)
Expected Outputs:
Terminal Report, Journal Article, Book Chapter, Policy Brief, Other
Research Focus:
Alignment with Sustainable Development Goals (SDGs)
Approval and Endorsement:
Dean/Director, Director of RCSSED, Vice Rector for Research and Innovation
Year:
2024
Region / city:
Australia
Topic:
Pharmacological treatment
Document type:
Pharmaceutical submission
Agency / institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Unknown
Target audience:
Medical practitioners, healthcare professionals
Period of validity:
Not specified
Approval date:
23 December 2024
Date of amendments:
Not specified
Year:
2021
Region / City:
Australia
Topic:
Pharmaceutical submission
Document type:
Submission report
Organization:
Novartis Pharmaceuticals Australia Pty Limited
Author:
Novartis Pharmaceuticals Australia Pty Limited
Target audience:
Healthcare professionals, regulatory bodies
Period of validity:
Ongoing
Approval date:
21 August 2002
Date of revisions:
18 December 2009, 11 March 2016, 8 July 2021, 16 July 2021, 29 July 2021
Note:
Contextual description
Year:
2023
Region / city:
Australia
Subject:
Medical treatment
Document Type:
Submission for drug listing approval
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
VIFOR PHARMA PTY LIMITED
Target audience:
Healthcare professionals, regulatory bodies
Period of validity:
N/A
Approval date:
17 January 2023
Date of changes:
N/A
Context:
The document is a pharmaceutical submission for the inclusion of avacopan on the Pharmaceutical Benefits Scheme (PBS) for the treatment of severe active granulomatosis with polyangiitis and severe active microscopic polyangiitis in combination with other medications.
Year:
2023
Region:
Wales
Country:
United Kingdom
Healthcare system:
NHS Wales
Document type:
Patient Group Direction
Medicine:
Fluconazole 150 mg capsule
Clinical indication:
Vulvovaginal candidiasis
Service framework:
Clinical Community Pharmacy Service
Service component:
Common Ailment Service
Authoring body:
Welsh Medicines Advice Service
Approving body:
Community Pharmacy Clinical Advisory Group
Target professionals:
Registered community pharmacists
Legal basis:
Human Medicines Regulations 2012
Operational start date:
1 July 2023
Review date:
31 March 2026
Expiry date:
30 June 2026
Version:
1.0
Approval date:
3 July 2023
Source type:
Regulatory and clinical governance document
Year:
2026
Region / City:
United Kingdom
Topic:
Eating Disorders, Binge Eating, Bulimia
Document Type:
Workshop Material
Organization:
New Maudsley Skills
Author:
Not specified
Target Audience:
Carers, Families affected by eating disorders
Effective Period:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
N/A
Region / City:
N/A
Subject:
Phenolic compounds, Polyphenol analysis
Document Type:
Research data
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Researchers, scientists
Period of validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Contextual description:
Research data on the identification of phenolic compounds in pomegranate extract using LC-MS analysis.
Year:
2021
Region / city:
Australia
Topic:
Medical treatment, pharmaceuticals
Document type:
Submission for Authority Required listing
Organization / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
PBAC
Target audience:
Healthcare professionals, regulatory bodies
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
July 2021
Year:
2021
Region / City:
Australia
Subject:
Pharmaceutical submission
Document Type:
Submission for listing
Organization / Institution:
Astellas Pharma Australia Pty Ltd
Author:
Astellas Pharma Australia Pty Ltd
Target Audience:
Medical practitioners, regulatory bodies
Effective Period:
Since April 2021
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2025
Region / City:
Not specified
Topic:
Medical procedures, Excluded services
Document Type:
Guideline
Author:
Not specified
Target Audience:
Healthcare providers, medical practitioners
Effective Period:
From 1/1/2025
Approval Date:
Not specified
Revision Date:
Not specified
Context:
This document provides an update on the status of capsule endoscopy for gastrointestinal tract imaging under Excluded Services Guidelines, highlighting its exclusion due to limited evidence of effectiveness and the existence of cost-effective alternatives.
Topic:
Chemistry of disinfectants and alcohol-based sanitizers
Subject Area:
Chemistry; Public Health
Type of Document:
Educational explanatory text
Author:
Not specified
Institution / Organization Mentioned:
FDA (Food and Drug Administration)
Context:
COVID-19 pandemic
Key Substances Discussed:
Ethanol (ethyl alcohol); Isopropyl alcohol (isopropanol); Water
Related Viruses:
SARS-CoV-2; Influenza virus; Herpes virus; Rhinovirus; Norovirus; HIV
Scientific Concepts:
Enveloped viruses; Nonenveloped viruses; Hydrogen bonding; Protein coagulation; Molecular structure
Purpose:
Explanation of why different alcohol concentrations are used in hand sanitizers
Sources Referenced:
pediaa.com; byjus.com; cancer.gov; ehs.umich.edu; lumenlearning.com; clutchprep.com; fda.gov
Approximate Period:
COVID-19 pandemic era (2020s)
Year:
2026
Location:
Pomona, NY, USA
Document Type:
Medical Instruction
Institution:
Digestive Disease Associates of Rockland, PC
Author:
Medical Staff
Target Audience:
Patients scheduled for capsule endoscopy
Procedure Duration:
6-8 hours
Preparation Requirements:
Clear liquid diet, bowel cleansing with Miralax, medication adjustments for diabetes and heart conditions
Special Considerations:
Patients with pacemakers or implanted defibrillators, diabetic medication adjustments, GLP-1 medication pause
Contact Information:
845-354-3700
Website:
www.ddar.com